阿司匹林是否被推荐用来预防VTE.pptVIP

* Key “takeaways”: AAOS guidelines “year of publication” restriction although technically sounds like a good idea because it only takes into consideration “newer” studies, Asprin, UFH, LMWH, are “old” products where many of the landmark clinical trails demonstrating efficacy in reducing DVT or PE were conducted well before 1996. Therefore, by limiting older studies, the AAOS analysis will miss out on huge body of evidence. Exclusion of metaanalyses may result in failure to take into account all the body of evidence available dealing with the subject Looking at studies where symptomatic PE was the main efficacy outcome will significantly limit the number of studies available for review due to the naturally low rates of symptomatic events. Furthermore, it may be questionable if studies where symptomatic PE was the main efficacy outcome was sufficiently powered to detect the difference in treatment groups. * Risk reduction with thromboprophylaxis after TKR is higher with LMWHs than with UFH and warfarin ASA only reduces risk by 13% Geerts WH et al. Chest. 2001;119:132S-175S * Risk reduction with thromboprophylaxis after TKR is higher with LMWHs than with UFH and warfarin ASA only reduces risk by 13% Geerts WH et al. Chest. 2001;119:132S-175S * Risk reduction with thromboprophylaxis after TKR is higher with LMWHs than with UFH and warfarin ASA only reduces risk by 13% Geerts WH et al. Chest. 2001;119:132S-175S * Risk reduction with thromboprophylaxis after TKR is higher with LMWHs than with UFH and warfarin ASA only reduces risk by 13% Geerts WH et al. Chest. 2001;119:132S-175S * Risk reduction with thromboprophylaxis after TKR is higher with LMWHs than with UFH and warfarin ASA only reduces risk by 13% Geerts WH et al. Chest. 2001;119:132S-175S * Risk reduction with thromboprophylaxis after TKR is higher with LMWHs than with UFH and warfarin ASA only reduces risk by 13% Geerts WH et al. Chest. 2001;119:132S-175S * Risk reduction with thromboprophylaxis